FGF19 is a biomarker associated with prognosis and immunity in colorectal cancer

The aim of this study was to investigate the relationship between fibroblast growth factor 19 (FGF19) and the prognosis and immune infiltration of colorectal cancer (CRC), and to find the related genes and pathways affecting the occurrence and development of CRC, providing an important molecular basis for the early diagnosis and immunotherapy of CRC. We performed Venn overlap analysis on prognosis-related genes of CRC and up-regulated differentially expressed genes (DEGs) of CRC and immune-related gene sets to obtain the final DEGs. We investigated the relationship between the target genes and pathological parameters, immune infiltration, and immune checkpoints. The relevant functions and signaling pathways of target genes were analyzed by enrichment analysis. We investigated the genetic variation of the target genes. We analyzed the association of target genes with tumor heterogeneity and drug sensitivity. Finally, we performed single-cell analysis of the target genes. The results indicate that FGF19 is a target gene associated with immunity and prognosis in CRC patients. By exploring the relationship between FGF19 and neutrophil extracellular traps (NETs), and the relationship between NETs and the immune microenvironment, we found that FGF19 may have an effect on the progression of CRC by promoting NETs expression leading to immune cell suppression.